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ABSTRACT
Ceftaroline is a novel cephalosporin recently
approved in children for treatment of acute
bacterial skin and soft tissue infections and
community-acquired bacterial pneumonia
(CABP) caused by methicillin-resistant
Staphylococcus aureus, Streptococcus pneumoniae
and other susceptible bacteria. With a favorable
tolerability profile and efficacy proven in
pediatric patients and excellent in vitro
activity against resistant Gram-positive and
Gram-negative bacteria, ceftaroline may serve
as a therapeutic option for polymicrobial
infections, CABP caused by penicillin- and
ceftriaxone-resistant S. pneumoniae and
resistant Gram-positive infections that fail
first-line antimicrobial agents. However,
limited data are available on tolerability in
neonates and infants younger than 2 months
of age, and on pharmacokinetic characteristics
in children with chronic medical conditions
and those with invasive, complicated
infections. In this review, the microbiological
profile of ceftaroline, its mechanism of action,
and pharmacokinetic profile will be presented.
Additionally, clinical evidence for use in
pediatric patients and proposed place in
therapy is discussed.
Keywords: Antibiotic resistance; Ceftaroline
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INTRODUCTION
Antibiotic resistance in Gram-positive bacteria is
steadily increasing, posing a growing health
concern worldwide [1, 2]. Likewise, antibiotic
treatment failures have been reported among
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children with invasive infections caused by
resistant Gram-positive bacteria [3, 4].
Management of these infections in pediatric
patients may be even more challenging due to
limited therapeutic options. Antibiotics approved
by the US Food and Drug Administration (FDA)
for treatment of infections caused by
methicillin-resistant Staphylococcus
aureus (MRSA) in children are limited to
vancomycin, clindamycin and linezolid [5].
Daptomycin has been increasingly used in
pediatrics despite the lack of safety and efficacy
data [6]. Finally, for newer antibiotics such as
telavancin, dalbavancin and oritavancin, the lack
of pharmacokinetic and clinical studies severely
restricts their use in pediatric infections [7].
Ceftaroline is a new cephalosporin with an
FDA-approved indications for acute bacterial
skin and skin structure infections (ABSSI)
caused by MRSA and community-acquired
bacterial pneumonia (CABP) caused by
Streptococcus pneumoniae and other susceptible
bacteria in children 2 months of age and older
[8]. In this review, the microbiological profile of
ceftaroline, its mechanism of action, and
pharmacokinetic characteristics will be
presented. Additionally, clinical evidence for
use in pediatric patients will be discussed.
Compliance with Ethics Guidelines
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Antimicrobial Activity and Pharmacology
of Ceftaroline
Ceftaroline is known as a novel
‘‘fifth-generation cephalosporin’’ that exhibits
in vitro bactericidal activity against MRSA
[9, 10]. It is also active against other bacteria
common in childhood infections, such as S.
pneumoniae, S. pyogenes, Haemophilus influenzae
and Moraxella catarrhalis [11].
Ceftaroline, like other b-lactams, exerts
bactericidal effects by binding to
penicillin-binding proteins (PBPs) to inhibit
cell wall synthesis [12]. Ceftaroline is
distinguished from other b-lactams by its
enhanced affinity for mutated PBPs that
render other b-lactams ineffective against S.
aureus and S. pneumoniae [13]. In S. aureus, the
mecA gene-encoded mutant PBP2a confers
methicillin resistance while b-lactam resistance
in S. pneumoniae results from modification in
PBP1A, PBP2X, and PBP2B [14, 15]. Unlike other
b-lactams, ceftaroline has unique greater
affinity for these altered PBPs by which it
retains activity against MRSA and
penicillin-resistant S. pneumoniae. Additionally,
ceftaroline has activity against commonly
encountered Gram-negative bacteria in
children including H. influenzae, Klebsiella
species and Escherichia coli. However, it does
not have activity against Gram-negative
bacteria producing extended-spectrum
b-lactamase (ESBL) or carbapenemase [16].
In international surveillance studies with
clinical isolates, ceftaroline MIC90 for MSSA
and MRSA were 0.25–0.5 mg/L and 1–2 mg/L,
respectively. Even though ceftaroline MICs for
MRSA isolates were four-fold higher than MSSA
isolates, a majority of S. aureus isolates were
susceptible to ceftaroline. Of note, ceftaroline
retained activity against heterogeneous
vancomycin-intermediate S. aureus, with MICs
ranging from 0.25 to 4 mg/L [16, 17].
Ceftaroline additionally exhibits excellent
activity against S. pneumoniae isolates
regardless of its susceptibility to other
antimicrobials, with MIC90 of B0.016 and
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0.25 mg/L for penicillin-susceptible and
penicillin-resistant S. pneumoniae isolates,
respectively [16]. Furthermore, it demonstrates
significant activity against
cephalosporin-resistant S. pneumoniae strains,
supporting its role in treatment of multi-drug
resistant S. pneumoniae infections [18].
Another potentially important
pharmacological characteristic is the low
propensity of Gram-positive pathogens to
develop resistance to ceftaroline. Mutant
selection did not occur in Gram-positive
bacteria evaluated in vitro, including S. aureus
and S. pneumoniae after repeated exposure to
ceftaroline [19, 20]. However, clinical
implication of the in vitro finding is not yet
fully understood, and the emergence of
resistance to ceftaroline during a course of
therapy has been reported, even though
extremely rare [21, 22]. Currently, prevalence
of ceftaroline-resistant organisms appears to be
fairly rare in surveillance studies conducted in
the United States, with 97.6% MRSA strains and
100% S. pneumoniae strains being susceptible to
ceftaroline [23, 24].
Pharmacokinetics
Basic pharmacokinetic parameters known to
date are based on adult studies. Ceftaroline is
administered as a water-soluble prodrug,
ceftaroline fosamil, which is rapidly
metabolized by a phosphatase enzyme to
bioactive ceftaroline and later hydrolyzed to
microbiologically inactive metabolite
ceftaroline M-1 [25]. It yields
dose-proportional increases in maximum
plasma concentration (Cmax) and area under
the curve (AUC) after administration of single
doses of 50–1000 mg. Repeated administration
of ceftaroline for 14 days appears to result in no
appreciable accumulation of the drug. Average
protein binding of ceftaroline is low, estimated
at *20% [8]. Ceftaroline is not substrate,
inducer or inhibitor of any major CYP
isoenzymes, minimizing potential for
drug–drug interactions [26]. Ceftaroline and its
metabolites are eliminated mainly by the
kidneys, necessitating dose adjustment for
renally impaired patients with creatinine
clearances of B50 mL/min [8, 27].
The pharmacodynamic (PD) parameter most
predictive of efficacy is the percentage of the
dosing interval during which serum-free
ceftaroline concentration remains above the
MIC (%fT[MIC). In a study using murine
thigh and lung infection models, the average
%fT[MIC needed for bacteriostasis was
26 ± 8% for S. aureus and 39 ± 9% for S.
pneumoniae [28]. A Monte Carlo simulation of
ceftaroline 600 mg every 12 h given to healthy
adults predicted fT[MIC of 71% and 51% for
organisms with MICs of 1 and 2 mg/L,
respectively. Probability of target attainment
of 40% fT[MIC was 100% at an MIC of 1 mg/L
and 90% at an MIC of 2 mg/L [29, 30].
In pediatric patients, approved ceftaroline
dosing regimens are 8 mg/kg every 8 h in
children from 2 months to\2 years of age. In
children and adolescents aged 2 years and older,
ceftaroline 12 mg/kg every 8 h is recommended
for patients weighing B33 kg, and 400 mg every
8 h or 600 mg every 12 h for those weighing
[33 kg. In population PK modeling and
simulations by Riccobene et al. [31], these
regimens were predicted to produce ceftaroline
exposure in children similar to that in adults
treated with ceftaroline 600 mg every 12 h. The
modeled dose regimens attained 36% fT[MIC
(median %fT[MIC associated with 1-log kill of
S. aureus) at a MIC of 2 mg/L in [90% of
children and 44% fT[MIC (median
%fT[MIC associated with 1-log kill of S.
pneumoniae) at MIC of 1 mg/L in 97% of
Infect Dis Ther (2017) 6:57–67 59
children [31]. With MIC90 of 1 mg/L and
0.12 mg/L for MRSA and S. pneumoniae in the
US, respectively [17, 24], currently approved
dosing regimens are predicted to maintain
adequate PD target in a majority of pediatric
patients. Of interest, ceftaroline 6 mg/kg every
8 h was expected to produce adequate
ceftaroline exposure and successful PD target
attainment in neonates and infants younger
than 2 months of age, which is being evaluated
in this specific pediatric population with
late-onset sepsis (NCT02424734) [31, 32].
However, special consideration should be
given to children with medical conditions that
may alter the pharmacokinetics of ceftaroline,
such as cystic fibrosis (CF). In these patients, the
b-lactams have an increased total body
clearance and larger volume of distribution
due to malnutrition and reduced adipose
tissue resulting in lower drug serum
concentrations [33]. In a report of a 6-year-old
CF patient with MRSA (ceftaroline MIC = 1 mg/
L) who was given a dose of *11 mg/kg every
8 h, the Cmax was 8.99 mg/L and %fT[MIC was
only 21% [34]. In contrast, non-CF children of
the same age group receiving the approved dose
of 12 mg/kg every 8 h had a Cmax of 27.6 mg/L
(90% prediction interval of 16.4–43.3 mg/L) and
85.2% fT[MIC (90% prediction interval of
61.7–100% T[MIC) [31, 34]. Even though the
patient clinically improved [34], the suboptimal
exposure in children with CF could lead to
emergence of ceftaroline resistance with
repeated exposure as reported by Cannavino
et al. [21]. Currently, very little data exist to
guide optimal ceftaroline dosing in children
with chronic medical conditions and
complicated disease states including CNS
infections and osteomyelitis. Pharmacokinetic
studies targeting children with these conditions
are on-going in the hope for further guidance in
the future [35–37].
Clinical Efficacy and Safety
FDA-Labeled Indications
In May 2016, the FDA approved ceftaroline for
the treatment of ABSSI and CABP among
children as young as 2 months of age [8]. This
approval was based on two randomized,
controlled observer-blinded studies primarily
evaluating safety in children [38, 39]. Study
doses were essentially the same as what is
currently approved (Table 1), with the
exception of increasing the dose from 8 mg/kg
to 12 mg/kg every 8 h for children
6 months–2 years of age. Additionally, the
study allowed for a maximum dose of 400 mg
every 8 h, but did not offer the alternative
option of 600 mg every 12 h as appears in the
package insert.
The CABP study compared ceftaroline to
ceftriaxone 75 mg/kg/day (maximum daily
dose of 4 g) and excluded patients with
suspected MRSA or Pseudomonas spp., or
requiring intensive care unit (ICU) admission.
Patients in both groups were treated for a mean
total of 10 days including initial intravenous
(IV) antibiotics for a minimum of 3 days plus
transition to oral therapy, which was typically
amoxicillin/clavulanate [38]. Within the
modified intent-to-treat (mITT) population
(i.e. received at least one dose of study drug),
clinical cure rates were comparable with 88%
(n = 94/107) success in the ceftaroline group
and 89% (n = 32/36) in the comparator group at
the test of cure (TOC) visit conducted between 8
and 15 days after cessation of therapy. In a
meta-analysis of 3 clinical trials evaluating
ceftaroline in adults hospitalized with severe
CABP (Pneumonia Outcomes Research Team
risk class 3–4), however, ceftaroline 600 mg
every 12 h was demonstrated to be superior to
ceftriaxone 1–2 g every 24 h as empiric
treatment. Of note, the therapeutic benefit of
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ceftaroline was not observed in a subgroup of
patients with prior antibiotic use within 96 h
[40].
The ABSSI study used the same dosing
scheme as the CABP trial and randomized
patients to receive ceftaroline or a comparator
regimen (vancomycin or cefazolin, with or
without aztreonam) [39]. Patients with serious
infections involving bones and joints, burns,
bite wounds and necrotizing infections were
excluded, as were those with pathogens not
susceptible to the study drugs. The median total
duration of therapy in each group was
approximately 10 days including initial IV
treatment plus oral cephalexin, clindamycin or
linezolid. Again, in the mITT population at the
TOC visit, the clinical cure rates were similar,
94% (n = 101/107) in the ceftaroline group
versus 87% (n = 45/52) in the comparator
group [39].
In both studies, incidences of
treatment-emergent adverse events were
comparable between ceftaroline and
comparators (45% vs. 46% in the CABP study;
22% vs. 23% in the ABSSI study). However, in
the CABP study, seroconversion to a positive
Direct Coombs’ test, a known effect of
ceftaroline, was observed in 17% (n = 19/112)
of patients in the ceftaroline group and 3% (1/
37) of patients in the ceftriaxone group.
Conversion rates were similar in the ABSSI
study (17/99, 17% in the ceftaroline group and
2/48, 4% in the comparator group) and no
events of hemolysis or hemolytic anemia
occurred in any of the patients who
experienced seroconversion [38, 39].
Off-Label Use
An additional pediatric clinical study compared
ceftaroline monotherapy to ceftriaxone plus
vancomycin for the treatment of complicated
CABP (cCABP) [41]. Included patients met the
same criteria previously used for enrollment in
the CABP study, plus one of several indicators of
complicated disease including empyema, ICU
admission or pleural effusion requiring chest
tube, plus acute symptom onset or worsening.
Ceftaroline dosing in this study differed from
past studies and what is available in the current
package insert; patients under 6 months of age
received 10 mg/kg/dose every 8 h, and patients
aged 6 months or older received 15 mg/kg/dose
every 8 h up to a maximum dose of 600 mg
every 8 h. Among the mITT population, clinical
Table 1 Approved and suggested ceftaroline dosing strategies
FDA approved Suggesteda
CABP and ABSSSI cCABP, CF, MRSA bacteremia/endocarditis
2 months to
\2 years
24 mg/kg/day divided every 8 h Age\6 months: 30 mg/kg/day divided every 8 h
Age 6 months to\2 years: 45 mg/kg/day divided every
8 h
2 to\18 years 36 mg/kg/day divided every 8 h
Maximum 1200 mg/day, divided every
8–12 h
45 mg/kg/day divided every 8 h
Maximum 1800 mg/day, divided every 8 h
FDA Food and Drug Administration, CABP community-acquired bacterial pneumonia, MRSA methicillin-resistant
Staphylococcus aureus, ABSSSI acute bacterial skin and skin structure infection, cCABP complicated community-acquired
bacterial pneumonia, CF cystic ﬁbrosis
a Limited data, not prospectively evaluated for safety outside of cCABP
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cure at the TOC visit was 90% (n = 26/29) for
patients who received ceftaroline and 100%
(n = 9/9) for those who received ceftriaxone
plus vancomycin. Treatment-emergent adverse
events occurred in 40% (n = 12/30) of the
ceftaroline group and 80% (n = 8/10) of the
vancomycin plus ceftriaxone group. The study
drug was discontinued secondary to adverse
events (increased liver enzymes and rash with
pruritis) in 2 patients, both in the ceftaroline
group. Similar to the other studies, 26% (n = 6/
23) of patients who received ceftaroline had
Direct Coombs test seroconversion, none of
whom experienced hemolysis or hemolytic
anemia [41].
The most common reported adverse drug
reactions for ceftaroline are rash, fever and
gastrointestinal effects [8]. Additionally,
transient blood dyscrasias have been described
in recent case reports including agranulocytosis
in both an adolescent and an adult [42, 43], and
a probable interaction between ceftaroline and
warfarin yielding a significantly
supratherapeutic INR in an adult patient [44].
A 10–20% incidence of neutropenia with
prolonged use has also been reported in
retrospective reviews of adult patients [45, 46].
As reviewed above, the ceftaroline doses
studied and ultimately approved for use in
children were derived from a PK model that
targeted exposures in children similar to those
in adults receiving 600 mg every 12 h [31].
However, higher doses up to 600 mg every 8 h
for adults and 10–15 mg/kg/dose every 8 h in
children have been described in case reports of
successful salvage treatment of invasive MRSA
infections including bacteremia and
endocarditis, and also cystic fibrosis
exacerbations [34, 47–51]. Similarly, in case
reports describing use of ceftaroline for
treatment of bacterial meningitis (4 S.
pneumoniae and 1 S. aureus) in 5 adults, 4
patients who received ceftaroline 600 mg every
8 h were successfully treated while 1 patient
receiving ceftaroline 600 mg every 12 h failed
the treatment, suggesting that higher doses
than currently approved may also be necessary
for successful treatment of meningitis in
children [52]. While the higher doses of
10–15 mg/kg/dose every 8 h were studied
prospectively in the pediatric cCABP trial, the
median duration of ceftaroline in that study was
9 days [41]. Salvage treatment of complicated
endovascular infections is anticipated to be
significantly longer, and retrospective data
indicate a higher incidence of neutropenia
among patients receiving ceftaroline for
prolonged duration. Thus, should prolonged
ceftaroline treatment be considered for salvage
treatment of an invasive infection, vigilant
monitoring for safety is warranted throughout
the entire treatment course.
Role in Therapy
While vancomycin currently remains the
preferred treatment for children with invasive
MRSA infections, its use is limited by PK
variability, toxicities and reported treatment
failure rates of between 30% and 50% among
children with MRSA bacteremia [53, 54]. As
such, pediatricians are often forced to consider
alternative treatments for serious infections
such as linezolid or daptomycin, each of
which has unique limitations. As a
bacteriostatic agent, linezolid is not preferred
for endovascular infections, and daptomycin is
not currently approved for use in children for
any indication [55, 56]. Therefore, ceftaroline
may be an attractive option given its
bactericidal effects and FDA approval for use
in children, but caution must be exercised as it
is not approved for invasive MRSA infections,
safety and efficacy data describing use outside of
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approved indications remain extremely limited,
and alternative dosing and monitoring
strategies are likely warranted.
Ceftaroline provides potent activity against
both MRSA and susceptible Enterobacteriaceae
in the absence of ESBL production, AmpC
induction or other resistance mechanisms.
While most data reviewed here describe the
beneficial role of ceftaroline in drug-resistant or
refractory Gram-positive infections, good
antimicrobial stewardship practice entails
selection of narrower spectrum antibiotics
targeted only toward confirmed and suspected
pathogens. Like other oxyimino cephalosporins
such as ceftazidime and ceftriaxone, ceftaroline
is a weak inducer of AmpC b-lactamase [57].
Comparably, exposure to ceftazidime or
ceftriaxone has been identified as an
independent risk factor for infection with
cephalosporin-resistant Enterobacter spp., a
pathogen well known to develop b-lactam
resistance per AmpC b-lactamase [58, 59], and
the same risks may be reasonably expected with
ceftaroline [57]. As such, ceftaroline may be best
positioned for the ideal, albeit uncommon,
scenario of concomitant infection with both
MRSA and Enterobacteriaceae [60], while use in
isolated Gram-positive infections should
potentially be reserved for intolerance or
failure of narrower spectrum antibiotics
targeted only against Gram-positive organisms
and for CABP by penicillin- or
ceftriaxone-resistant S. pneumoniae strains.
CONCLUSION
Ceftaroline is a new cephalosporin with activity
against bacteria commonly encountered in
pediatric infections including MRSA,
penicillin-resistant and other
cephalosporin-resistant S. pneumoniae isolates,
H. Influenzae as well as non-ESBL-producing
Enterobacteriaceae spp. It is approved for
management of ABSSI caused by MRSA and
CABP caused by S. pneumoniae and other
susceptible bacteria in children over 2 months
of age. With potent activity against a wide
spectrum of bacteria and efficacy and safety
established in children, ceftaroline may serve as
a valuable antibiotic in cases of antibiotic
intolerance or failure of first-line antibiotics in
Gram-positive, CABP caused by suspected or
proven penicillin- or ceftriaxone resistant S.
pneumoniae strains, and polymicrobial
infections with MRSA and some
Gram-negative bacteria.
Despite these therapeutic benefits in
children, limited information is available
evaluating its use in management of more
serious infections that may warrant more
aggressive therapy. In addition,
pharmacokinetic data in neonates and infants
younger than 2 months of age are lacking.
Clinical trials are on-going to address the
clinical question of how to optimally treat
children with CF, CNS infections and
osteomyelitis. Like other antibiotics, the excess
and inappropriate use will likely lead to
antibiotic resistance. Additionally, ceftaroline
like other oxyimino cephalosporins will likely
induce the production of AmpC b-lactamase
among Enterobacter species [57]. Thus,
ceftaroline will need to be monitored by
institutional antimicrobial stewardship
programs to assure its use is reserved for
appropriate clinical situations.
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